
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2133240/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Medicine, 2021, 47, 188-198. | 3.9 | 237 |
| 2 | Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19. Chest, 2021, 160, 187-198. | 0.4 | 164 |
| 3 | New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1287-1297. | 2.5 | 142 |
| 4 | Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493. | 2.9 | 116 |
| 5 | Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376. | 4.6 | 109 |
| 6 | Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. Translational Research, 2021, 236, 147-159. | 2.2 | 91 |
| 7 | Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. EBioMedicine, 2017, 24, 231-236. | 2.7 | 69 |
| 8 | Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Critical Care, 2021, 25, 177. | 2.5 | 69 |
| 9 | Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 546-556. | 2.5 | 65 |
| 10 | Evaluation of the 2016 Infectious Diseases Society of America/American Thoracic Society Guideline Criteria for Risk of Multidrug-Resistant Pathogens in Patients with Hospital-acquired and Ventilator-associated Pneumonia in the ICU. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 826-830. | 2.5 | 46 |
| 11 | Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. Critical Care, 2022, 26, 11. | 2.5 | 46 |
| 12 | Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. European Respiratory Journal, 2018, 51, 1702215. | 3.1 | 45 |
| 13 | International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. Journal of Infection, 2019, 79, 300-311. | 1.7 | 36 |
| 14 | Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest, 2019, 155, 795-804. | 0.4 | 34 |
| 15 | Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551. | 1.3 | 31 |
| 16 | Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respiratory Research, 2018, 19, 261. | 1.4 | 28 |
| 17 | SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. Annals of the American Thoracic Society, 2020, 17, 1164-1168. | 1.5 | 28 |
| 18 | Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. PLoS ONE, 2017, 12, e0182436. | 1,1 | 28 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS ONE, 2018, 13, e0200504. | 1.1 | 27 |
| 20 | Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia. Journal of Clinical Medicine, 2019, 8, 843. | 1.0 | 27 |
| 21 | An international perspective on hospitalized patients with viral community-acquired pneumonia. European Journal of Internal Medicine, 2019, 60, 54-70. | 1.0 | 26 |
| 22 | Clinical management of community acquired pneumonia in the elderly patient. Expert Review of Respiratory Medicine, 2016, 10, 1211-1220. | 1.0 | 25 |
| 23 | Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE, 2017, 12, e0178022. | 1.1 | 25 |
| 24 | Invasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia. Critical Care, 2019, 23, 51. | 2.5 | 24 |
| 25 | New aspects in the management of pneumonia. Critical Care, 2016, 20, 267. | 2.5 | 23 |
| 26 | Assessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired Pneumonia. Microorganisms, 2020, 8, 103. | 1.6 | 23 |
| 27 | The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. Critical Care, 2021, 25, 331. | 2.5 | 23 |
| 28 | Higher frequency of comorbidities in fully vaccinated patients admitted to the ICU due to severe COVID-19: a prospective, multicentre, observational study. European Respiratory Journal, 2022, 59, 2102275. | 3.1 | 23 |
| 29 | Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. Respiratory Research, 2018, 19, 119. | 1.4 | 21 |
| 30 | Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. Scientific Reports, 2018, 8, 9236. | 1.6 | 21 |
| 31 | One Year Overview and Follow-Up in a Post-COVID Consultation of Critically III Patients. Frontiers in Medicine, 0, 9, . | 1.2 | 21 |
| 32 | Antimicrobial Resistance Among Streptococcus pneumoniae. , 2018, , 13-38. | | 20 |
| 33 | Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525. | 1.3 | 18 |
| 34 | Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. Annals of the American Thoracic Society, 2021, 18, 257-265. | 1.5 | 18 |
| 35 | One-year mortality after ICU admission due to COVID-19 infection. Intensive Care Medicine, 2022, 48, 366-368. | 3.9 | 18 |
| 36 | Sepsis and community-acquired pneumonia. Annals of Research Hospitals, 0, 2, 7-7. | 0.0 | 17 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. Critical Care, 2019, 23, 251. | 2.5 | 17 |
| 38 | Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Medicine, 2022, 48, 850-864. | 3.9 | 17 |
| 39 | Bronchial Aspirate-Based Profiling Identifies MicroRNA Signatures Associated With COVID-19 and Fatal Disease in Critically III Patients. Frontiers in Medicine, 2021, 8, 756517. | 1.2 | 16 |
| 40 | Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. Chest, 2017, 152, 295-303. | 0.4 | 15 |
| 41 | Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. Emerging Microbes and Infections, 2022, 11, 1537-1549. | 3.0 | 15 |
| 42 | Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. Chest, 2017, 151, 1311-1319. | 0.4 | 13 |
| 43 | ICU-Acquired Pneumonia Is Associated with Poor Health Post-COVID-19 Syndrome. Journal of Clinical Medicine, 2022, 11, 224. | 1.0 | 12 |
| 44 | Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. Critical Care, 2021, 25, 432. | 2.5 | 11 |
| 45 | Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units. Archivos De Bronconeumologia, 2022, 58, 22-31. | 0.4 | 10 |
| 46 | Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study. Clinical Infectious Diseases, 2018, 67, 958-961. | 2.9 | 9 |
| 47 | Adjunctive Therapies for Community-Acquired Pneumonia. Clinics in Chest Medicine, 2018, 39, 753-764. | 0.8 | 9 |
| 48 | Diagnostic accuracy of Gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2020, 26, 1456-1463. | 2.8 | 9 |
| 49 | Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Medicine Experimental, 2021, 9, 61. | 0.9 | 9 |
| 50 | Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. Journal of Clinical Medicine, 2019, 8, 1461. | 1.0 | 7 |
| 51 | Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection. American Journal of Health-System Pharmacy, 1997, 54, 1065-1068. | 0.5 | 6 |
| 52 | Safety considerations of current drug treatment strategies for nosocomial pneumonia. Expert Opinion on Drug Safety, 2021, 20, 181-190. | 1.0 | 6 |
| 53 | ESICM LIVES 2016: part one. Intensive Care Medicine Experimental, 2016, 4, . | 0.9 | 5 |
| | | | |

Score for Differentiating Pleural Tuberculosis from Malignant Effusion. Medical Sciences (Basel,) Tj ETQq000 rgBT [Qverlock 10 Tf 50 62] 1.3

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. European Respiratory Journal, 2020, 56, 2000773. | 3.1 | 5 |
| 56 | Age is a determinant of short-term mortality in patients hospitalized for an acute exacerbation of COPD. Internal and Emergency Medicine, 2021, 16, 401-408. | 1.0 | 5 |
| 57 | Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. Annals of the American Thoracic Society, 2021, 18, 807-814. | 1.5 | 4 |
| 58 | Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study. European Respiratory Journal, 2022, 59, 2100620. | 3.1 | 3 |
| 59 | Rapid identification of antimicrobial resistance patterns allows a faster antibiotic adequacy. Critical Care, 2017, 21, 208. | 2.5 | 2 |
| 60 | Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. Antibiotics, 2021, 10, 798. | 1.5 | 2 |
| 61 | Human Adiaspiromycosis: A Case From Argentina. Chest, 2013, 144, 220A. | 0.4 | 1 |
| 62 | Usefulness of Adenosine Deaminase Assay in Diagnosis of Patients with HIV Infection and Pleural Tuberculosis. Medical Sciences (Basel, Switzerland), 2018, 6, 101. | 1.3 | 1 |
| 63 | Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study. Journal of Clinical Medicine, 2020, 9, 3508. | 1.0 | 1 |
| 64 | Ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2020, 33, 1. | 1.3 | 1 |
| 65 | Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. , 2017, , . | | 1 |
| 66 | Risk factors for MDR pneumonia according to the 2017 International ERS/ESICM/ESCMID/ALAT guidelines. , 2019, , . | | 1 |
| 67 | Evaluation of Respiratory Sequelae in Patients With COVID-19, Where we are and Where we are Going. CIBERESUCICOVID and RECOVID Studies to Compare Patients Admitted to ICU vs Conventional Ward. Archivos De Bronconeumologia, 2022, 58, T115-T116. | 0.4 | 1 |
| 68 | Risk factors for community-acquired pneumonia in adults. Minerva Respiratory Medicine, 2017, 56, . | 0.1 | 0 |
| 69 | Response. Chest, 2019, 156, 415. | 0.4 | 0 |
| 70 | The War against Bad Bugs: Fighting the Resistance. Journal of Clinical Medicine, 2020, 9, 2563. | 1.0 | 0 |
| 71 | Validation of the PES Prediction Score for the Causative Different to Treat Microorganisms in Community-Acquired Pneumonia. , 2020, , . | | 0 |
| 72 | Hospital-Acquired and Ventilator-Associated Pneumonia. , 2022, , 206-219. | | 0 |

ADRIAN CECCATO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Bronchiectasis in rare pulmonary diseases: A case series. Community Acquired Infection, 2016, 3, 129. | 0.1 | Ο |
| 74 | A new wave of influenza A: Description of a cohort of patients in 2013 from a general hospital in Buenos Aires, Argentina. Community Acquired Infection, 2016, 3, 123. | 0.1 | 0 |
| 75 | Usefulness of real time-polymerase chain reaction (RT-PCR) in the diagnosis of ICU-acquired pneumonia (ICUAP). , 2016, , . | | О |
| 76 | Microbiological vs non-microbiological confirmed nnventilator ICU-acquired pneumonia. , 2016, , . | | 0 |
| 77 | Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia. , 2016, , . | | Ο |
| 78 | The impact of septic shock on intensive care unit-acquired pneumonia survival is not homogenous. , 2017, , . | | 0 |
| 79 | Interpretation of biomarkers at emergency department depends on onset of symptoms in community-acquired pneumonia. , 2017, , . | | 0 |
| 80 | Time to Blood Culture Positivity as a Predictor of Clinical Outcomes and Severity in Adults with Bacteremic Pneumococcal Pneumonia. , 2017, , . | | 0 |
| 81 | Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP?. , 2017, , . | | О |
| 82 | Microorganisms resistant to conventional antimicrobial treatment in acute exacerbation of COPD. , 2017, , . | | 0 |
| 83 | Myobacterium kansasii as the Primary Etiology of Pulmonary Infections due to Non-Tuberculous Mycobacterium (NTM) in Patients Without Human Immunodeficiency Virus (HIV): Experience from a Center in Buenos Aires, Argentina. The University of Louisville Journal of Respiratory Infections, 2018, 2 | 0.2 | Ο |
| 84 | Eosinophil count on admission is not a good biomarker in severe exacerbations of COPD to predic later readmission: a long term observational study from the AECOPD-Barcelona Cohort. , 2018, , . | | 0 |
| 85 | Twenty-year Trend in Mortality among Hospitalized Patients with Pneumococcal Community-Acquired Pneumonia. , 2018, , . | | Ο |
| 86 | LYMPHOPENIA AS PREDICTOR OF LONG TERM MORTALITY IN PATIENTS WITH HOSPITAL ACQUIRED PNEUMONIA. , 2018, , . | | 0 |
| 87 | Acute Respiratory Distress Syndrome in Mechanically-Ventilated Patients with Community-Acquired Pneumonia. , 2018, , . | | Ο |
| 88 | Follow-up cultures in ventilator-associated pneumonia. , 2019, , . | | 0 |
| 89 | Effect of corticosteroids on inflammatory markers in patients with severe cap and high inflammatory response according to presence of lymphopenia. , 2019, , . | | Ο |
| 90 | PES Score validation in a multicenter Cohort of patients with community-acquired pneumonia. , 2019, , . | | 0 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Are carbapenems a better antibiotic than others for treat ICU-AP? A post-hoc analysis of a prospective cohort. , 2020, , . | | 0 |
| 92 | Severe community-acquired pneumonia. , 0, , 101-116. | | 0 |
| 93 | Use of corticosteroids in patients with severe CAP admitted to ICU, experience in a real-life setting. , 2020, , . | | 0 |
| 94 | Defining Clinical and Microbiological Nonresponse in Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, , . | 0.8 | 0 |